Exact Sciences Corporation
EXAS
Κατάταξη σε μετοχές
#1158
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Τιμή μετοχής
$104.91
Τελευταίος συγχρονισμός: 2026-03-23
Κεφαλαιοποίηση
$20.03B
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
65.45%
Χώρα
US
Εμπόριο Exact Sciences Corporation (EXAS)
Κατηγορία
Healthcare
Έσοδα για την Exact Sciences Corporation (EXAS)
Έσοδα τον Dec 2025 TTM: $3.25B
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Exact Sciences Corporation, τα τρέχοντα έσοδα της εταιρείας (TTM) είναι $3.25B. Το 2024, η εταιρεία είχε έσοδα $2.76B αύξηση σε σχέση με τα έσοδα του έτους 2023, τα οποία ήταν $2.50B. Τα έσοδα είναι το συνολικό ποσό που παράγει μια εταιρεία από τις πωλήσεις προϊόντων ή υπηρεσιών. Σε αντίθεση με τα κέρδη, δεν αφαιρούνται έξοδα.
Ιστορικό εσόδων για την Exact Sciences Corporation από 2000 έως 2026
Έσοδα στο τέλος κάθε έτους
| Έτος | Έσοδα | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $3.25B | 0.00% |
| 2025 | $3.25B | 17.69% |
| 2024 | $2.76B | 10.37% |
| 2023 | $2.50B | 19.93% |
| 2022 | $2.08B | 17.95% |
| 2021 | $1.77B | 18.49% |
| 2020 | $1.49B | 70.19% |
| 2019 | $876.29M | 92.82% |
| 2018 | $454.46M | 70.86% |
| 2017 | $265.99M | 167.66% |
| 2016 | $99.38M | 151.99% |
| 2015 | $39.44M | 2,093.38% |
| 2014 | $1.80M | -56.61% |
| 2013 | $4.14M | 0.00% |
| 2012 | $4.14M | -0.46% |
| 2011 | $4.16M | -22.10% |
| 2010 | $5.34M | 12.32% |
| 2009 | $4.76M | -648.79% |
| 2008 | $-867.00K | -129.54% |
| 2007 | $2.94M | -38.21% |
| 2006 | $4.75M | 11.76% |
| 2005 | $4.25M | -13.88% |
| 2004 | $4.94M | 70.11% |
| 2003 | $2.90M | 223.41% |
| 2002 | $897.00K | 1,663.32% |
| 2001 | $50.87K | 0.00% |
| 2000 | 0.00 | 0.00% |
Έσοδα για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Έσοδα | Διαφορά Εσόδων | Χώρα |
|---|---|---|---|
| $46.34B | 1,327.04% |
US
|
|
| $25.11B | 673.24% |
US
|
|
| $2.71B | -16.63% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 127.04% |
US
|
